News round-up by DDW’s Megan Thomas for 6 – 10 September
DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.
New potential therapy for schizophrenia patients
Newron Pharmaceuticals has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia. Results from the study are expected by the fourth quarter of 2022.
Partnership for commercialisation of Parkinson’s drug in Europe
BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.
Data shows promise for patients with asthma and comorbid nasal polyps
New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.
Exscientia and Gates Foundation’s antiviral therapeutics
Exscientia has entered a four-year collaboration with the Bill & Melinda Gates Foundation to develop small molecule therapeutics that tackle the current coronavirus pandemic and help prepare for future pandemics.
New mass spectrometry portfolio to advance quantitative analysis
According to Thermo Fisher Scientific, lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can use its new mass specrometry (MS) portfolio and chromatography solutions to accelerate throughput and improve sensitivity to meet rapidly changing regulatory requirements and the fast responses needed to tackle emerging human and environmental health risks.
